Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
- Associated Therapies
- -
Effects of Mesna on Homocysteine in Kidney Failure
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00524199
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00473551
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 22
- Registration Number
- NCT00450801
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00439361
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00432094
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2016-11-29
- Target Recruit Count
- 14
- Registration Number
- NCT00429416
- Locations
- 🇺🇸
Thomas Jefferson University', Philadelphia, Pennsylvania, United States
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 9
- Registration Number
- NCT00424489
- Locations
- 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00410488
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Lymphodepletion Plus Adoptive Cell Transfer with or Without Dendritic Cell Immunization in Patients with Metastatic Melanoma
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1230
- Registration Number
- NCT00338377
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-09-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00290433
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.